| Literature DB >> 28160947 |
Parth J Parekh1, Raj Majithia2, Sanjay K Sikka1, Todd H Baron3.
Abstract
Pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography, with the potential for clinically significant morbidity and mortality. Several patient and procedural risk factors have been identified that increase the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Considerable research efforts have identified several pharmacologic and procedural interventions that can drastically affect the incidence of PEP. This review article addresses the underlying mechanisms at play for the development of PEP, identifying patient and procedural risk factors and meaningful use of risk-stratification information, and details current interventions aimed at reducing the risk of this complication.Entities:
Mesh:
Year: 2017 PMID: 28160947 DOI: 10.1016/j.mayocp.2016.10.028
Source DB: PubMed Journal: Mayo Clin Proc ISSN: 0025-6196 Impact factor: 7.616